US2015231205A1PendingUtilityA1

Compositions and methods for the treatment of myocardial ischemia/reperfusion injury with annexin a1 short peptide

Assignee: UNIV DUKEPriority: Oct 16, 2009Filed: Jan 27, 2015Published: Aug 20, 2015
Est. expiryOct 16, 2029(~3.2 yrs left)· nominal 20-yr term from priority
C07K 5/1019A61K 38/1709C07K 7/06C07K 14/47A61K 38/07A61K 38/08A61P 9/10
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a method of treating, ameliorating or preventing myocardial ischemia/reperfusion injury in a subject in need thereof, by administering to the subject a therapeutically effective amount of an ANXA1short peptide (ANXA1sp).

Claims

exact text as granted — not AI-modified
1 . A method of treating myocardial ischemia/reperfusion injury in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an ANXA1 short peptide (ANXA1sp). 
     
     
         2 . A method of ameliorating myocardial ischemia/reperfusion injury in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an ANXA1 sp. 
     
     
         3 . (canceled) 
     
     
         4 . The method of  claim 1 , wherein the myocardial ischemia/reperfusion injury is perioperative. 
     
     
         5 . The method of  claim 1 , wherein the subject is normoglycemic. 
     
     
         6 . The method of  claim 1 , wherein the subject is hyperglycemic. 
     
     
         7 . A kit for the treatment, amelioration or prevention of myocardial ischemia/reperfusion injury in a subject in need thereof, comprising an ANXA1sp and instructions for use in the treatment, amelioration or prevention of myocardial ischemia/reperfusion injury in a subject in need thereof. 
     
     
         8 . The kit of  claim 7 , wherein the myocardial ischemia/reperfusion injury is perioperative. 
     
     
         9 - 15 . (canceled)

Join the waitlist — get patent alerts

Track US2015231205A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.